| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.9 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |